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Abstract
Background: For decades, the efficacy of interventions in clinical trials enrolling dogs with atopic dermatitis (AD)
relied on heterogeneous evaluations of skin lesions and pruritus using unvalidated tools. Although some
instruments for clinical signs were validated later, there was little impact on standardizing outcome measures
resulting in difficulties in comparing treatment efficacy between trials and impeding meta-analyses.
Results: Participants in the Outcome Measures subcommittee of the International Committee of Allergic Diseases of
Animals (ICADA) collaborated for two years to develop a core outcome set (COS) for canine AD, the COSCAD. This
project involved several steps, constantly-re-assessed during online exchanges, to define the scope of this COS, to
identify the relevant stakeholders, the domains to be evaluated, the instruments available for measuring agreed-upon
domains and how to express outcome measures. This COSCAD’18 was designed principally for therapeutic—but not
preventive or proactive—clinical trials enrolling dogs with chronic, nonseasonal (perennial), moderate-to-severe AD.
Selected domains were skin lesions, pruritus manifestations and perception of treatment efficacy. Instruments to
evaluate these domains were the CADESI4 or CADLI, the 10-point pruritus visual analog scale (PVAS10) and the Owner
Global Assessment of Treatment Efficacy (OGATE), respectively. The COSCAD’18 has three outcome measures: the
percentages of dogs with veterinarian-assessed skin lesions or owner-rated pruritus manifestation scores in the range
of normal dogs or those with mild AD; the third is a good-to-excellent global assessment by the pet owners of their
perception of treatment efficacy. Importantly, this COSCAD’18 is not meant to represent the sole—or
primary—outcome measures evaluated in a trial; authors are always free to add any others, which they deem will best
assess the efficacy of tested interventions. Benchmarks to define a threshold for treatment success were not set, as
what constitutes a clinically-relevant therapeutic efficacy is expected to vary greatly depending upon interventions.
Conclusions: This COSCAD’18 should help veterinarians and owners compare the benefits of treatments in future
trials. This COS should also facilitate the combination of trial results in future systematic reviews, thereby producing
more reliable summary estimates of treatment effects and enhancing evidence-based veterinary dermatology.
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For the last three decades, clinicians have tested the effi-
cacy of pharmacological and biological interventions to
treat canine atopic dermatitis (AD). Three systematic re-
views of clinical trial results—especially those performed
in the last millennium—revealed that the therapeutic ef-
ficacy was assessed by outcome measures that varied
greatly between investigating teams [1–3]. The domains
evaluated in these trials were most often global assess-
ments of the drug’s efficacy, or the assessment of one or
more signs or symptoms.
At first, investigators used non-validated instruments
(i.e., tools or scales) devised ad hoc or de novo to suit
the various purposes. As a result, comparing the efficacy
of the various therapeutic interventions was often un-
clear due to the profusion and variability of instruments
and outcome measures used. Additionally, this inconsist-
ency meant that one could not combine results in mean-
ingful meta-analyses.
Since the beginning of this millennium, some instru-
ments—or versions and variants thereof—were proposed
in an attempt to standardize (or one could say
“objectivize”) the evaluation of the cardinal signs of canine
AD. The use of newly-validated instruments to measure
the skin lesion and pruritus manifestation domains, for ex-
ample the last two versions of the Canine Atopic Derma-
titis Extent and Severity Index (CADESI3 or CADESI4)
[4–6], the Canine Atopic Dermatitis Lesion Index
(CADLI) [7] and Hill’s 10-point Pruritus Visual Analog
Scale (PVAS10) [8, 9] was a notable improvement toward
standardizing the evaluation of atopic dogs during trials.
Unfortunately, there was still no universal consensus on
which instruments to use, when and how to use them,
and what would be considered an endpoint threshold for
a clinically-relevant outcome or treatment “success”.
Other authors took the liberty to transform these instru-
ments by arbitrarily selecting and/or changing some of the
evaluated lesions (i.e. the so-called “modified/mCADESIs”)
[10, 11].
In recent trials used to support the approval of drugs
for treatment of canine AD, clinicians most often used,
as outcome measures, a 50% or greater reduction of
baseline CADESI and PVAS values (i.e., the so-called
CADESI-50, PVAS-50) [12–15] as a halving in the
CADESI2 scores was shown to correlate highly with an
overall assessment of treatment efficacy by both owners
and clinicians [13]. Meanwhile, investigators also pro-
posed a drug to be antipruritic if it led, a minima, to a
2-cm reduction out of a 10-cm PVAS [14]. Recently, in a
large trial of a new therapeutic monoclonal antibody, the
percentage reductions from baseline CADESI3 and
PVAS values and the percentage of dogs whose endpoint
CADESI3 and PVAS values were in the range of those of
normal dogs were chosen [16]. As a result of such vari-
ability in selected outcome measures, the comparison of
treatment effect between trials is still not always possible
or even relevant.
In 2015, the International Committee of Allergic Dis-
eases of Animals (ICADA) launched a subcommittee
with the goal of proposing a “core outcome set” (COS)
for clinical trials enrolling dogs with AD. Such COS
would represent a small number of nonexclusive out-
come measures, accepted by relevant stakeholders, to be
assessed and reported in all clinical studies of similar de-
sign [17]. This COS would be a minimum set common
to all trials. We wish to emphasize that a COS does not
preclude investigators from measuring a host of other
outcomes as needed for their study, nor does it mean
that any of the COS measures need to be considered as
a primary outcome measure.
In order to enhance our ability to compare and com-
bine future therapeutic trials of canine AD, we sought to
establish a COS for this disease. We report herein the
development of the first COS in the field of veterinary
dermatology: the 2018 Core Outcome Set for Canine
Atopic Dermatitis (COSCAD’18) from the ICADA.
Whenever applicable and relevant, this project was re-
ported according to the recommendations of the Core




The protocol was not registered beforehand due to the
lack of relevant veterinary medicine registry for such
purpose.
Participants
We aimed to assemble a small group of ICADA mem-
bers from either private specialty work or university
practices, all with interest and experience in clinical tri-
als and/or tool development for canine AD.
Consensus process - design of the COSCAD’18
The design process of this COS evolved from addressing
a series of questions in sequence; these were:
Step 1: What is the scope of the COSCAD, i.e. for what
type of patients and trials should this COS be designed?
Step 2: What stakeholders would have to be consulted
on the relevance of the chosen COS?
Step 3: Which domains should be selected for
evaluation in this COS?
Step 4: Which instrument (s) should be used for each
selected domain?
Step 5: Which outcome measures using selected
instruments should ultimately be included in this COS?
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Step 6: What would be desirable mode of reporting of
the study COS?
Throughout the first half of 2016, subcommittee mem-
bers worked on the successive steps of developments,
via resources shared online, using a voting scheme that
could be amended continuously while an issue was being
reviewed.
During the de facto development phase of this COS
(i.e. steps 3 to 5), all subcommittee members shared a file
in which anybody could propose domains to be evalu-
ated, the instruments to score these domains, and, ul-
timately, outcome measures using domain-instrument
combinations. At the same time, each member had the
constant opportunity to modify and vote on proposals
made by others. Each individual step lasted until a con-
sensus among at least 70% of members (i.e. five of seven)
was reached on the specific points being discussed.
After the first draft of the COSCAD emerged, it was
sent, in successive phases, to the stakeholders identified
in the Step 2 above using a combination of direct email
exchanges and the completion of online forms. After
each review phase, the proposed draft of the COSCAD
was reassessed in the context of comments provided by
the evaluators; this step provided an opportunity for an
additional review and COSCAD modification before the
proposal was sent out to the subsequent stakeholder
group.
After this position paper was finally drafted, its con-
tent was agreed upon not only by all subcommittee
member authors, but it was also approved unanimously
by all ICADA members who reviewed it (18/18 mem-
bers; 100%).
Ethics and consent
We did not identify any relevant conflict of interest rele-
vant to the development of this COS. While all subcom-
mittee participants have received honoraria for
consulting and/or lecturing or research support from
commercial companies involved in animal health, this
COS was not associated with any specific intervention
or brand. Furthermore, all companies that had a drug
approved specifically for treatment of canine AD were
consulted in the third phase of stakeholder consultation.
Three members of this subcommittee (PBH, TO, JP) had
been involved in the development of the only validated
instruments evaluating skin lesions [6, 7] and pruritus
manifestations [9] in dogs with AD.
Results
Participants
Throughout the two years of development of this COS-
CAD’18, we had eight geographically-dispersed partici-
pants: Emmanuel Bensignor (specialty practice, multiple
locations, France), Claude Favrot (University of Zurich,
Switzerland), Craig Griffin (specialty practice, San Diego,
California, USA), Peter Hill (University of Adelaide,
Australia), Ralf Mueller (Ludwig-Maximilian University,
Munich, Germany), Thierry Olivry (chair, NC State Uni-
versity, Raleigh, North Carolina, USA) and Jon Plant
(specialty practice, Portland, Oregon).
COSCAD development
Step 1: Scope
Participants reached a consensus that this COSCAD’18
should be proposed for all therapeutic—but not prevent-
ive, prophylactic or proactive—clinical trials enrolling dogs
with chronic, nonseasonal (or perennial), moderate-
to-severe AD.
A description of the methodology for diagnosing AD
was beyond the purview of this subcommittee, but we
expected that trialists enrolling subjects would diagnose
AD mainly based on the classic clinical characteristics of
this disease [19]. Furthermore, when developing this
COS, we did not consider whether or not to evaluate
dogs with environmental allergen-associated AD differ-
ently from those with food-induced AD or mixed IgE
sensitization patterns [20], as these distinctions would
have been made by investigators at the time of study de-
sign and atopic dog enrolment.
Step 2: Stakeholders
A consensus was reached to have evolving drafts of the
COSCAD’18 reviewed, in successive phases, by all
groups interested in the assessment of efficacy of inter-
ventions tested in clinical trials enrolling dogs with AD,
as follows:
Phase I: the entire membership of the ICADA.
Phase II:
– Board-certified veterinary dermatologists from
existing specialty Colleges (American College of
Veterinary Dermatology [ACVD], European College
of Veterinary Dermatology [ECVD], Asian College
of Veterinary Dermatology [AiCVD], and the
Dermatology Chapter of the Australian and New
Zealand College of Veterinary Scientists
[ANZCVSc]).
– atopic dog owners from various geographical areas.
Phase III:
– Representatives from the animal health companies
that had at least one approved drug for treatment of
canine AD.
– Editors from the veterinary journals that had
recently published articles reporting results of
relevant clinical trials enrolling dogs with AD.
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Phase IV:
– Representatives from the three largest administrative
departments that have recently evaluated clinical
trials for approval of drugs for treatment of canine
AD in Europe and the USA (e.g. European
Medication Agency (EMA), the Center for
Veterinary Medicine of the US Food and Drug
Administration [CVM-FDA] and the US
Department of Agriculture [USDA]).
Step 3: Evaluated domains
The subcommittee members eventually reached a unani-
mous agreement to assess the following three domains
for therapeutic clinical trials enrolling atopic dogs:
1. A veterinarian-reported assessment of skin lesions
2. An owner-reported assessment of pruritus manifes-
tations (e.g. scratching, licking, rubbing, biting …)
3. An owner-reported global assessment of treatment
efficacy
Step 4: Instruments for domain evaluation
The subcommittee members were unanimous in their
selection of the following instruments to assess the three
domains above:
1. For the veterinarian-assessed skin lesions: the 4th
version of the Canine Atopic Dermatitis Extent and
Severity Index (CADESI4) or the Canine Atopic
Dermatitis Lesions Index (CADLI).
2. For the owner-assessed pruritus manifestations: the
pruritus visual analog scale (PVAS) with category
descriptors validated by Hill and Rybnicek with
values translatable into a possible 10 points with a
single decimal (PVAS10 from 0.0 to 10.0).
3. For the owner-reported global assessment of treat-
ment efficacy: a subjective five-point Owner Global
Assessment of Treatment Efficacy (OGATE) was
proposed (Table 1).
The first three instruments (CADESI4/CADLI/PVAS)
were identified easily, as these are the only ones with
published reports of a combination of either validity,
reliability, sensitivity to change or thresholds for severity
levels [6–9]; these tools were logical choices due to their
popularity and use in clinical trials for many years.
While we considered the time to administer the skin
lesion-grading instrument in our evaluation processs,
the limited time needed to grade skin lesions with either
CADESI4 and CADLI (both with median grading times
of less than 5 min) makes them easy to use when seeing
patients, and they were considered equivalent in this
regards [6].
The subcommittee members do recognize, however,
that the OGATE is not a validated instrument, but at the
time of development of this COSCAD, a validated global
“patient-oriented outcome measure” could not be iden-
tified in any previously-published clinical trials identi-
fied in the three available systematic reviews [1–3].
Notwithstanding this caveat, the subcommittee mem-
bers unanimously agreed that such OGATE would
capture the owner’s perception of the benefit of the
proposed treatment, a parameter of highest importance
as it would have some implications on the adherence to
the prescribed regimen and the quality of life of the
patient and its owner (s).
Step 5: Use of selected instruments as outcome measures in
the COSCAD’18
While authors of articles reporting results of clinical tri-
als enrolling dogs with AD will naturally be free to use
any one or combination of outcome measures of their
choice, the members of this subcommittee recommend
that reported efficacy measures for relevant trials include
at least the COS below.
This COSCAD’18 is composed of the following three
outcome measures, which should be reported for each
tested intervention, be it an active one, a placebo, a sin-
gle drug or a combination regimen:
1. CADESI4/CADLI (normal-to-mild)
This outcome measure, to be abbreviated
CADESI4-N2M or CADLI-N2M, corresponds to
the percentage of dogs with veterinarian-assessed
skin lesion scores in the range of normal dogs or
those with mild AD at study end (i.e. dogs with
CADESI4 < 35 or CADLI < 8).
(Example of future reporting: X% of the dogs had
skin lesion scores of normal dogs or those with
mild AD after being treated with drug Y for Z
weeks)
2. PVAS10 (normal-to-mild)
This outcome measure, to be abbreviated PVAS10-
N2M, tallies the percentage of dogs with owner-
assessed pruritus manifestation scores in the range
of normal dogs or those with mild AD at study end
(i.e. dogs with PVAS10 < 3.6).
Table 1 Owner Global Assessment of Treatment Efficacy
(OGATE)
Question: How would you rate the overall response to treatment?
Answer: select only one of the following five answers:
0 - No response
1 – a poor response
2 – a fair response
3 – a good response
4 – an excellent response
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Example of future reporting: X% of the dogs had
pruritus manifestation levels of normal dogs or
those with mild AD after being treated with drug Y
for Z weeks.
3. OGATE (good-to-excellent)
This outcome measure, to be abbreviated OGATE-
G2E, represents the percentage of dogs whose
owner rated the overall response to treatment as
“good” or “excellent” (i.e. OGATE > 2).
Example of future reporting: X% of owners
evaluated that treatment with the drug Y for Z
weeks had a good-to-excellent response.
Readers should be mindful that this COSCAD’18 was
designed for dogs with moderate-to-severe AD at the
time of enrolment in a clinical trial. In case the investi-
gators were to wish to enroll dogs with skin lesions and/
or pruritus manifestations representing mild AD, then
the two primary outcome measures would have to be
changed to “… scores in the range of those of normal
dogs”. The CADESI4-N, CADLI-N and PVAS10-N
threshold values would then change to less than 10, 6
and 2.0, respectively.
Furthermore, researchers should be conscious that
the CADESI4 and CADLI evaluate, among others,
some skin lesions (e.g. lichenification and self-induced
alopecia) that will not be sensitive to change in
short-term trials lasting less than 6 weeks. As a re-
sult, this COSCAD’18 will be most relevant and rep-
resentative of the true intervention’s efficacy in trials
lasting 6 weeks or longer.
Finally, and most importantly, while this COSCAD’18
is designed to include three separate outcome measures
to be used in clinical trials, it does not define bench-
marks that would constitute a clinically-relevant treat-
ment success by themselves. Indeed, such assessment is
likely to vary depending upon the potency and charac-
teristics of the intervention tested. As a result, this sub-
committee leaves the approving authorities in the
various countries to define what percentage of atopic
dogs enrolled in the various trials coming under their re-
view should meet which benchmark as a primary efficacy
measure; the selected outcome measures could be
among those included in the COSCAD’18, or they could
be any other.
Further details on the four phases of evaluation of the
COSCAD’18 by the different stakeholders is available
online as Additional file 1.
Step 6: Recommendations for data reporting
There was consensus among subcommittee members
that, to have a better depiction of the treatment effect,
the reporting of study results in journal articles should
have, in addition to the COSCAD’18, a minimum degree
of standardization.
We recommend the reporting to include, ideally, all of
the following:
1. a comprehensive online supplementary table with
all individual subjects pre- and post-treatment
CADESI4/CADLI and PVAS10 values and post-
treatment OGATE (Additional file 2).
2. an online supplementary or in-article published
scatter plot figures with all pre- and post-treatment
CADESI4/CADLI and PVAS10 (Additional file 3),
and
3. a published table reporting the number and
percentage of dogs with CADESI4/CADLI and
PVAS10 values in the different severity categories at
the various evaluation time points (a minima those
before and after treatment [Additional file 4]).
Discussion
Main findings
In this paper, the Outcome Measures Subcommittee of
the ICADA reports the design of the COSCAD’18, the
first COS for therapeutic trials enrolling dogs with non-
seasonal moderate-to-severe AD. This COSCAD’18 con-
tains three outcome measures.
The first two evaluate domains (skin lesions and prur-
itus manifestations) and use validated instruments that
are already widely-known to the veterinary dermatology
community. At this time, veterinarians are familiar with
the reporting of percentage changes from baseline
CADESI/CADLI/PVAS10 values during trials. While a
50% reduction in values (e.g. a CADESI-50) has been
used for over 15 years [12, 13], members of this subcom-
mittee were not supportive of using such outcome meas-
ure because of its dependency upon baseline values
resulting in heterogeneous reductions in the score them-
selves. For example, a treatment-induced 50% reduction
in a severely itchy dog with a baseline PVAS10 of 10.0
corresponds to a 5-point grade reduction and a residual
score corresponding to a moderate pruritus level likely
to be found unacceptable by most owners. In contrast,
the same 50% reduction in a dog with a moderate prur-
itus level and a baseline PVAS10 of 3.8 will lead to a 1.9
grade change and an ending level of pruritus corre-
sponding to that of a normal dog.
As a result, instead of percentage changes from base-
line scores (the so-called “deltas”), we preferred to have
the COSCAD’18 include the percentage of dogs having
skin lesion and pruritus manifestation scores in the
range of those of normal dogs or those with mild AD at
trial’s end. It was felt that, ultimately, the veterinarians
and dog owners would prefer to know how likely the
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treatment would make their patient/pet looking normal
or having only residual mild signs and symptoms of AD.
As a third outcome measure, we proposed to use the
OGATE, an owner-assessed global evaluation of their
perception of the efficacy of the treatment used in
their pet. While this instrument has not been formally
validated per se, the subcommittee participants felt
that such an evaluation was one that would matter
most to pet owners, as it would influence treatment
adherence and the quality of life of their pet. We wish
to point out, however, that a close ancestor of this
OGATE—then named the OGA-E, “E” for “Efficacy”—
had been first proposed as part of the evaluation of the
sensitivity to change of the CADESI4 [6]; the OGA-E
was significantly and highly correlated with the per-
centage reduction from baseline of the CADESI4 after a
therapeutic intervention [6]. This observation suggests
that the higher the post-treatment reduction in skin lesion
scores, the higher the owner’s assessment of efficacy
would be of such treatment, a logical and clinically-
relevant expectation.
Limitations
The main limitation in the design of this COSCAD’18 is
the relatively small size of the communitiy involved in
its development and stakeholder validation, which could
be perceived as a source of bias. While it would have
been ideal to involve all identified stakeholders in the
early selection of the domains, tools and outcome mea-
sures, the global audience targeted and the lack of inde-
pendent financial resources to assemble large audiences
were deterrents to such achievement. Nevertheless,
each successive draft of the COSCAD’18 was influenced
by the feedback of the preceding stakeholder groups.
Indeed, each online poll had a comment box for sur-
veyed individuals to leave a feedback including add-
itional outcome measures. Additionally, during the
later phases of the stakeholder consultation (Phases III
and IV), consultees were allowed more time and they
did not have to use a predefined format; most answered
in a lengthier fashion documenting the rationale of
their evaluation.
A second limitation is our proposed use of the
formally-unvalidated OGATE and its perception of sub-
jectivity that contrasts with that of a more “objective”
assessment of lesion and pruritus manifestation scores
with the CADESI4/CADLI and PVAS10, respectively.
While this subcommittee’s participants agreed that the
OGATE is in need of a proper validation, readers should
keep in mind that the CADESI4 and CADLI merely rep-
resent aggregated subjective scores of individual signs or,
for the PVAS10, symptoms; the OGATE should then
only be seen as a similar subjective evaluation of a per-
ception of treatment efficacy.
Implications for research
There are several research needs that derive from the
development of this COSCAD’18.
Firstly, the subcommittee participants could not de-
cide which one of the CADESI4 or CADLI should be
preferred, as both were found to evaluate the same do-
mains, lesions, and their scores have been shown to cor-
relate highly; a significant 86% correlation was found
between CADESI4 and CADLI values in [6]. In spite of
these two scoring systems being deemed equivalent, fur-
ther studies should determine which one might perform
best in atopic dogs of varying severities, so that future
COSCAD updates only propose one of these instru-
ments for simplicity purposes.
Secondly, the OGATE itself should be evaluated, a
minima, for its validity and reliabilty, as described previ-
ously [21]. Its sensitivity to change between weak and
potent interventions, and between short and longer
courses thereof, must also be quantified.
During the process of domain selection, the partici-
pants in this subcommittee considered including “quality
of life (QoL)” as a parameter. While there are two in-
struments proposed for the evaluation of the QoL in
dogs with skin diseases [22–25], the subcommittee
members considered these instruments overtly compli-
cated and in need of further simplification and ensuing
validation.
Finally, in most recent trials testing interventions in
humans with AD, outcome measures have often in-
cluded an “Investigator Global Assessment (IGA)” of
“clear-or-almost clear”. While there is no universal
agreement on a standard and validated instrument to as-
sess this IGA [26], such an outcome measure would
likely be highly relevant in trials enrolling dogs with AD.
Indeed, an IGA could serve to increase the validity of
the assessments of two of the COSCAD’18 outcome mea-
sures with which the IGA would be expected to correlate:
the CADESI4/CADLI-N2M and the PVAS10-N2M. As
there is currently no IGA available for use in dogs with
AD, the design and validation of such an instrument could
be a valuable tool to be used in future trials.
Implications for practice
While the various instruments discussed above were de-
signed for their use in clinical trials enrolling dogs with
AD, it is possible that one or more—especially the sim-
ple OGATE—could be useful to veterinarians in the
follow-up of treatment of their patient dogs with AD.
Such usefulness needs to be tested appropriately.
Conclusion
With this COSCAD’18, the Outcome Measure Subcom-
mittee of the ICADA hopes to provide a new standard
for the standardization of the reporting of clinical trials
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enrolling dogs with AD. Our aim is not to stifle investi-
gator independence, but to harmonise study outcomes
in order to make a better sense of future studies. Study
authors, whether animal health company employees or
independent investigators, are encouraged to include
this COSCAD’18, either as a stand-alone outcome set or
as part of their trials’ selected outcome measures. It is
also hoped that other relevant stakeholders (drug ap-
proval authorities, journal editors and article reviewers)
will work together to generalize the use of this COS-
CAD’18. Hopefully, this will allow the entire veterinary
community, and most importantly the pet owners, to be
better prepared in their shared decision making when
comparing the various interventions available to treat
dogs with AD.
Additional files
Additional file 1: This file contains the specific data corresponding to
the evaluation of the proposed COSCAD’18 by the various stakeholders.
(DOCX 137 kb)
Additional file 2: a. Example of desirable comprehensive online
supplementary table with all individual subjects pre- and post-treatment
COSCAD’18 values. b. Example of desirable tables for reporting the COS-
CAD’18 with possible relevant statistical analyses. (XLSX 51 kb)
Additional file 3: a. Example of desirable scatter plot figure. b. Example
of desirable after-vs-before figure. (TIF 1258 kb)
Additional file 4: Example of in-article table with data categorization
and possible relevant statistical analyses. (XLSX 32 kb)
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